Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome Academic Article Article uri icon


MeSH Major

  • Genetic Testing
  • High-Throughput Nucleotide Sequencing
  • Polycystic Kidney, Autosomal Dominant


  • Unresponsive autoimmune haemolytic anaemia (AIHA) may require therapy with second-line drugs. There is no consensus that any one of these agents is more effective than another. Mycophenolate mofetil (MMF) is an immunosuppressive drug proven to be effective in reducing renal allograft rejection as well as being used in autoimmune diseases including systemic lupus erythematosus (SLE). We describe its use in two patients who were treated with MMF for AIHA in the context of underlying SLE and antiphospholipid syndrome (APS). The patients showed a good response to treatment with MMF, suggesting a possible role in the treatment of AIHA.

publication date

  • September 2003



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1191/0961203303lu419cr

PubMed ID

  • 12945724

Additional Document Info

start page

  • 633

end page

  • 635


  • 12


  • 8